Is Agomab Therapeutics NV halal to invest in?

According to Musaffa's Shariah screening methodology, Agomab Therapeutics NV (AGMB) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Agomab Therapeutics NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Agomab Therapeutics NV using these criteria to determine its compliance status.

Can Muslims buy shares of Agomab Therapeutics NV?

Muslim investors may consider investing in Agomab Therapeutics NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Agomab Therapeutics NV classified as NOT HALAL?

Musaffa determines the Shariah status of Agomab Therapeutics NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Agomab Therapeutics NV updated?

The Shariah compliance status of Agomab Therapeutics NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Agomab Therapeutics NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Agomab Therapeutics NV?

You can check the latest Shariah compliance status of Agomab Therapeutics NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

AGMB Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: February 27, 2026

Report Source: 2025 3rd Quarter Report

Agomab Therapeutics NV. Stock Analysis AGMB

United States Health Care Small Cap Report: Q3, 2025

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. The firm is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The firm also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

Key Statistics of Agomab Therapeutics NV (AGMB)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$10.40$11.03

Today's Open

$11.03

Volume

42.83K

P/E Ratio (TTM)

52 Week Range

$9.00$17.45

Market Cap

589.96M

Avg. Volume

134.63K

Dividend Yield

Financial Metrics & Statements of Agomab Therapeutics NV (AGMB)

FAQ's for Agomab Therapeutics NV (AGMB)

According to Musaffa’s Shariah screening methodology, Agomab Therapeutics NV (AGMB) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.